Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early

Cancer

Volumn 117, Issue 9, 2011, Pages 1819-1826

  Dawood, Shaheenah ^a,b   Ueno, Naoto T ^a   Valero, Vicente ^a   Woodward, Wendy A ^a   Buchholz, Thomas A ^a   Hortobagyi, Gabriel N ^a   Gonzalez Angulo, Ana Maria ^a   Cristofanilli, Massimo ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b DUBAI HOSPITAL   (United Arab Emirates)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

inflammatory breast cancer; locally advanced breast cancer; multidisciplinary management; prognosis; survival

Indexed keywords

ANTHRACYCLINE; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY BREAST CANCER; LOCALLY ADVANCED BREAST CANCER; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SEGMENTAL MASTECTOMY;

BREAST NEOPLASMS; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MIDDLE AGED; POPULATION SURVEILLANCE; PROGNOSIS; SEER PROGRAM; SURVIVAL RATE;

EID: 79955439847     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25682     Document Type: Article

References (30)

1. Levine PH, Steinhorn SC, Ries LG, Aron JL., Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst. 1985; 74: 291-297. (Pubitemid 15112115)
2. Lee BJ, Tannenbaum EN., Inflammatory carcinoma of the breast. Surg Gynecol Obstet. 1924; 39: 580-595.
3. Haagensen C., Diseases of the Breast. 2nd ed. Philadelphia: WB Saunders; 1971: 576-584.
4. Kim T, Lau J, Erban J., Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: a systematic review. Clin Breast Cancer. 2006; 5: 386-395. (Pubitemid 46157559)
5. Bozzetti F, Saccozzi R, Lena MD, Salvadori B., Inflammatory cancer of the breast: analysis of 114 cases. J Surg Oncol. 1981; 18: 355-361. (Pubitemid 12202325)
6. Low J, Berman A, Steinber S, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004; 22: 4067-4074. (Pubitemid 41185175)
7. Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997; 40: 321-329. (Pubitemid 27276136)
8. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH., Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005; 97: 966-975. (Pubitemid 41430562)
9. Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM., Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004; 22: 4067-4074. (Pubitemid 41185175)
10. Panades M, Olivotto IA, Speers CH, et al. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol. 2005; 23: 1941-1950. (Pubitemid 46211373)
11. Cristofanilli M, Valero V, Buzdar AU, et al. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007; 110: 1436-1444. (Pubitemid 47463056)
12. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M.D. Anderson Cancer Center experience. Clin Breast Cancer. 2004; 4: 415-419. (Pubitemid 38443464)
13. Hankey BF, Ries LA, Edwards BK., The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999; 8: 1117-1121. (Pubitemid 30004912)
14. Breast. In:, Green FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer- Verlag; 2002: 225-281.
15. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
16. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008; 26: 44-53.
17. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Freeman J, Goodwin JS., Impact of a scientific presentation on community treatment patterns for primary breast cancer. J Natl Cancer Inst. 2006; 98: 382-388.
18. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21: 976-983. (Pubitemid 46594124)
19. Woodward WA, Buchholz TA., The role of locoregional therapy in inflammatory breast cancer. Semin Oncol. 2008; 35: 78-86. (Pubitemid 351282389)
20. Liao Z, Strom EA, Buzdar AU, et al. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys. 2000; 47: 1191-2000.
21. Bristol IJ, Woodward WA, Strom EA, et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2008; 72: 474-484.
22. Damast S, Ho AY, Montgomery L, et al. Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era. Int J Radiat Oncol Biol Phys. 2010; 77: 1105-1112.
23. van Golen KL, Wu ZF, Qiao XT, et al. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000; 60: 5832-5838.
24. van Golen KL, Davies S, Wu ZF, et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res. 1999; 5: 2511-2519. (Pubitemid 29437336)
25. Bertucci F, Finetti P, Rougemont J, et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res. 2004; 64: 8558-8565. (Pubitemid 39552068)
26. Colpaert CG, Vermeulen PB, Benoy I, et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer. 2003; 88: 718-725. (Pubitemid 36411451)
27. Wedam SB, Low JA, Yang XC, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006; 24: 769-777. (Pubitemid 46622044)
28. Guerin M, Gabillot M, Mathieu MC, et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer. 1989; 43: 201-208. (Pubitemid 19062410)
29. Parton M, Dowsett M, Ashley S, et al. High incidence of HER-2 positivity in inflammatory breast cancer. Breast. 2004; 13: 97-103. (Pubitemid 38443604)
30. Dawood S, Ueno NT, Valero V, et al. Incidence of and survival following brain metastases among women with inflammatory breast cancer. Ann Oncol. 2010 May 3. [Epub ahead of print].